Mark Boer
Member of the Board of Advisors @ Medicxi
Almere, The Netherlands
Mark Boer is a startup investor at Medicxi in Almere. Mark was formerly with Index Ventures, which he joined in 2005 as a Venture Partner. He has been involved in many investments, including Comentis, Molecular Partners (SWX:MOLN), PanGenetics (acquired by Abbott), ProFibrix (acquired by The Medicines Company) and Versartis (Nasdaq: VSAR). He is an advisor to the Utrecht University TechnologyTransfer Office and Holdings. He has worked for, managed and founded a number of early-stage biopharmaceutical companies in the field of innovative novel biopharmaceuticals.Mark graduated in Biochemistry and has a PhD from the University of Amsterdam.
Last updated:
For AI agents: llms.txt
About Medicxi
Medicxi is an investment firm that focuses on the life sciences sector. It was established in 2016 by the former Index Ventures life sciences team, who have been active for over 20 years and have significant experience in drug discovery and the development of therapeutics for unmet medical needs.
Medicxi Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Giovanni Pericolini
Finance Director & CFO
|
|||
Kevin Johnson
Co-Founder & Partner
|
|||
|
Mark Boer
Member of the Board of Advisors
|
|||
Michele Bauer
Co-Founder & Partner
|
|||
Trevor Baglin
Venture Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
FAQ
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
